BACKGROUND: Butyrylcholinesterase (BChE) is an alpha-glycoprotein found in the nervous system and liver. Its serum level is reduced in many clinical conditions, such as liver damage, inflammation, injury, infection, malnutrition, and malignant disease. In this study, we analyzed the potential prognostic significance of preoperative BChE levels in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP). METHODS: We retrospectively evaluated 535 patients with PCa who underwent RP from 1996-2014 at a single institution. Serum BChE was routinely measured in all patients before operation. Covariates included age, preoperative laboratory data [prostate-specific antigen (PSA), hemoglobin, total protein, albumin, BChE, lactate dehydrogenase, C-reactive protein], clinical T, biopsy Gleason score, D'Amico risk classification, and RP with/without neoadjuvant therapy. Univariate and multivariate analyses were performed to identify clinical factors associated with biochemical recurrence-free survival (BRFS). Univariate analyses were performed using the Kaplan-Meier and log-rank methods, and multivariate analysis was performed using a Cox proportional hazard model. RESULTS: The median BChE level was 255 U/L (normal range 168-470 U/L). The median age of the enrolled patients was 68 years, and the median PSA level at diagnosis of PCa was 8.39 ng/mL. The median follow-up period was 65 months. The 5-year BRFS rate was 72.9 %. The 5-year BRFS rates in the BChE ≥ 168 and ≤ 167 U/L groups were 77.7 and 55.0 %, respectively (P < 0.001). In univariate analysis, BChE, cT, biopsy Gleason score, and D'Amico risk classification were significantly associated with BRFS. Multivariate analysis revealed that BChE was significantly associated with BRFS. CONCLUSIONS: This study validated preoperative serum BChE levels as an independent prognostic factor for PCa after RP.
BACKGROUND:Butyrylcholinesterase (BChE) is an alpha-glycoprotein found in the nervous system and liver. Its serum level is reduced in many clinical conditions, such as liver damage, inflammation, injury, infection, malnutrition, and malignant disease. In this study, we analyzed the potential prognostic significance of preoperative BChE levels in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP). METHODS: We retrospectively evaluated 535 patients with PCa who underwent RP from 1996-2014 at a single institution. Serum BChE was routinely measured in all patients before operation. Covariates included age, preoperative laboratory data [prostate-specific antigen (PSA), hemoglobin, total protein, albumin, BChE, lactate dehydrogenase, C-reactive protein], clinical T, biopsy Gleason score, D'Amico risk classification, and RP with/without neoadjuvant therapy. Univariate and multivariate analyses were performed to identify clinical factors associated with biochemical recurrence-free survival (BRFS). Univariate analyses were performed using the Kaplan-Meier and log-rank methods, and multivariate analysis was performed using a Cox proportional hazard model. RESULTS: The median BChE level was 255 U/L (normal range 168-470 U/L). The median age of the enrolled patients was 68 years, and the median PSA level at diagnosis of PCa was 8.39 ng/mL. The median follow-up period was 65 months. The 5-year BRFS rate was 72.9 %. The 5-year BRFS rates in the BChE ≥ 168 and ≤ 167 U/L groups were 77.7 and 55.0 %, respectively (P < 0.001). In univariate analysis, BChE, cT, biopsy Gleason score, and D'Amico risk classification were significantly associated with BRFS. Multivariate analysis revealed that BChE was significantly associated with BRFS. CONCLUSIONS: This study validated preoperative serum BChE levels as an independent prognostic factor for PCa after RP.
Entities:
Keywords:
Biochemical recurrence-free survival; Biomarker; Butyrylcholinesterase; Prostate cancer
Authors: C Mitrache; J R Passweg; J Libura; L Petrikkos; W O Seiler; A Gratwohl; H B Stähelin; A Tichelli Journal: Ann Hematol Date: 2001-05 Impact factor: 3.673
Authors: Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin Journal: Urology Date: 2007-06 Impact factor: 2.649
Authors: Vicky Ping Chen; Yang Gao; Liyi Geng; Robin J Parks; Yuan-Ping Pang; Stephen Brimijoin Journal: Proc Natl Acad Sci U S A Date: 2015-02-02 Impact factor: 11.205
Authors: Indranil Chattopadhyay; Jianmin Wang; Maochun Qin; Lingqiu Gao; Renae Holtz; Robert L Vessella; Robert W Leach; Irwin H Gelman Journal: Oncotarget Date: 2017-02-07
Authors: Noemi Pavo; Markus Raderer; Georg Goliasch; Raphael Wurm; Guido Strunk; Anna Cho; Johannes F Novak; Heinz Gisslinger; Günther G Steger; Michael Hejna; Wolfgang Köstler; Sabine Zöchbauer-Müller; Christine Marosi; Gabriela Kornek; Leo Auerbach; Sven Thorben Schneider; Bernhard Parschalk; Werner Scheithauer; Robert Pirker; Barbara Kiesewetter; Richard Pacher; Christoph Zielinski; Martin Hülsmann Journal: Oncotarget Date: 2017-04-16
Authors: Eva Valentina Klocker; Dominik Andreas Barth; Jakob Michael Riedl; Felix Prinz; Joanna Szkandera; Konstantin Schlick; Peter Kornprat; Karoline Lackner; Jörg Lindenmann; Herbert Stöger; Michael Stotz; Armin Gerger; Martin Pichler Journal: Cancers (Basel) Date: 2020-05-04 Impact factor: 6.575